<?xml version="1.0" encoding="utf-8"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en"><title>News on Elan Corporation Plc</title><link href="http://earningsandlosses.com/topic/elan-corporation-plc" rel="alternate"></link><id>http://earningsandlosses.com/topic/elan-corporation-plc</id><updated>2010-10-27T16:00:47Z</updated><entry><title>Summary Box: Irish drugmaker Elan suffers loss</title><link href="http://earningsandlosses.com/earnings-and-losses/summary-box-irish-drugmaker-elan-suffers-loss-3482233a" rel="alternate"></link><updated>2010-10-27T16:00:47Z</updated><author><name>AP News</name></author><id>tag:earningsandlosses.com,2010-10-27:/earnings-and-losses/summary-box-irish-drugmaker-elan-suffers-loss-3482233a/</id><summary type="html">&lt;div id="subtitle"&gt;Summary Box: Drugmaker Elan sees $43.6 million net loss in 3rd quarter&lt;/div&gt;&lt;div&gt;&lt;p&gt;THE BASICS: Irish drugmaker &lt;span&gt;&lt;a title="Elan Corporation plc" href="/topic/Elan+Corporation+plc" &gt;Elan Corp.&lt;/a&gt;&lt;/span&gt; reported a third-quarter net loss as it paid down debts, cut research and development costs, and focused on increasing sales of drugs that combat multiple sclerosis.&lt;/p&gt;&lt;p&gt;MS DRUGS: Elan's share of revenue from its major MS fighter, &lt;span id="tysabri" class="inform"&gt;&lt;a tit...</summary><category term="Company Activities and Information"></category><category term="Corporate Reporting"></category><category term="Earnings and Losses"></category><category term="Biotechnology Sector"></category><category term="Pharmaceuticals Sector"></category><category term="United States"></category><category term="Tysabri"></category><category term="Elan Corporation plc"></category><category term="Ampyra"></category></entry><entry><title>Irish drugmaker Elan suffers $43.6M net loss in Q3</title><link href="http://earningsandlosses.com/earnings-and-losses/irish-drugmaker-elan-suffers-436m-net-loss-q3-3370318a" rel="alternate"></link><updated>2010-10-27T03:30:18Z</updated><author><name>AP Features</name></author><id>tag:earningsandlosses.com,2010-10-27:/earnings-and-losses/irish-drugmaker-elan-suffers-436m-net-loss-q3-3370318a/</id><summary type="html">&lt;div&gt;&lt;p&gt;Irish drugmaker &lt;span&gt;&lt;a title="Elan Corporation plc" href="/topic/Elan+Corporation+plc" &gt;Elan Corp.&lt;/a&gt;&lt;/span&gt; reported a third-quarter net loss of $43.6 million (euro31.6 million) Wednesday as it paid down debts, cut research and development costs, and focused on increasing sales of drugs that combat multiple sclerosis.&lt;/p&gt;&lt;p&gt;Elan has struggled to record net profits since 2002, when the company experienced research setbacks and an accounting scandal.&lt;/p&gt;&lt;p&gt;In the third quarter of 2009,...</summary><category term="Company Activities and Information"></category><category term="Corporate Reporting"></category><category term="Earnings and Losses"></category><category term="Autoimmune Disorders"></category><category term="Multiple Sclerosis"></category><category term="Geriatric Medicine"></category><category term="Alzheimer's Disease"></category><category term="United States"></category><category term="Tysabri"></category><category term="Clinical Immunology"></category><category term="Biogen Idec Inc."></category><category term="Elan Corporation plc"></category><category term="Brain and Nerve Health"></category><category term="Bitly Inc."></category><category term="Ampyra"></category></entry><entry><title>Drugmaker Elan Posts Narrower Loss In 1st Quarter</title><link href="http://earningsandlosses.com/earnings-and-losses/drugmaker-elan-posts-narrower-loss-1st-quarter-3386506a" rel="alternate"></link><updated>2010-10-27T06:53:32Z</updated><author><name>Drugs.com</name></author><id>tag:earningsandlosses.com,2010-10-27:/earnings-and-losses/drugmaker-elan-posts-narrower-loss-1st-quarter-3386506a/</id><summary type="html">...</summary><category term="Company Activities and Information"></category><category term="Corporate Reporting"></category><category term="Earnings and Losses"></category><category term="Autoimmune Disorders"></category><category term="Multiple Sclerosis"></category><category term="Biotechnology Sector"></category><category term="Pharmaceuticals Sector"></category><category term="United States"></category><category term="New Jersey"></category><category term="Tysabri"></category><category term="Clinical Immunology"></category><category term="New Brunswick"></category><category term="Thomson Reuters Corporation"></category><category term="Biogen Idec Inc."></category><category term="Elan Corporation plc"></category><category term="Brain and Nerve Health"></category></entry><entry><title>Irish drugmaker Elan records Q4 loss, sees rebound</title><link href="http://earningsandlosses.com/earnings-and-losses/irish-drugmaker-elan-records-q4-loss-sees-rebound-842981a" rel="alternate"></link><updated>2010-04-16T07:09:12Z</updated><author><name>AP News</name></author><id>tag:earningsandlosses.com,2010-04-16:/earnings-and-losses/irish-drugmaker-elan-records-q4-loss-sees-rebound-842981a/</id><summary type="html">&lt;div id="subtitle"&gt;Irish drugmaker Elan records 4th-quarter loss, sees 2010 rebound amid strong &lt;a title="Tysabri" href="/topic/Tysabri" &gt;Tysabri&lt;/a&gt; sales&lt;/div&gt;&lt;div&gt;&lt;p&gt;&lt;a title="Elan Corporation plc" href="/topic/Elan+Corporation+plc" &gt;Elan Corp. PLC&lt;/a&gt; said Wednesday it slumped to a loss in the fourth quarter, but the Irish drugmaker forecast a 2010 rebound as sales for its key multiple sclerosis-fighting drug, Tysabri, continue to grow.&lt;/p&gt;&lt;p&gt;The &lt;a title="Dublin (Ireland)" href="/topic/Dubl...</summary><category term="Corporate Reporting"></category><category term="Earnings and Losses"></category><category term="Autoimmune Disorders"></category><category term="Multiple Sclerosis"></category><category term="Biotechnology Sector"></category><category term="Pharmaceuticals Sector"></category><category term="United States"></category><category term="New Jersey"></category><category term="Europe"></category><category term="Ireland"></category><category term="Tysabri"></category><category term="Clinical Immunology"></category><category term="New Brunswick"></category><category term="Irish Stock Exchange"></category><category term="Biogen Idec Inc."></category><category term="Elan Corporation plc"></category><category term="Brain and Nerve Health"></category><category term="Dublin (Ireland)"></category></entry><entry><title>Eye On Stocks For Monday, March 6</title><link href="http://earningsandlosses.com/earnings-and-losses/eye-stocks-monday-march-6-1859845a" rel="alternate"></link><updated>2010-10-14T08:01:48Z</updated><author><name>Forbes</name></author><id>tag:earningsandlosses.com,2010-10-14:/earnings-and-losses/eye-stocks-monday-march-6-1859845a/</id><summary type="html">...</summary><category term="Company Activities and Information"></category><category term="Corporate Reporting"></category><category term="Earnings and Losses"></category><category term="Financial Markets"></category><category term="Market Analysis"></category><category term="Consumer Electronics Manufacturing"></category><category term="Biotechnology Sector"></category><category term="Pharmaceuticals Sector"></category><category term="Electronics Sector"></category><category term="Semiconductor Manufacturing"></category><category term="Analog and Mixed-Signal Chip Manufacturing"></category><category term="Telecommunications Sector"></category><category term="Wireless Telecommunications"></category><category term="Wireless Telephone Manufacturing"></category><category term="Wall Street"></category><category term="Bank of America Corporation"></category><category term="Standard &amp; Poor's"></category><category term="Food and Drug Administration"></category><category term="Merck &amp; Co. Inc."></category><category term="Tysabri"></category><category term="Vioxx"></category><category term="BlackBerry Mobile Devices"></category><category term="Research In Motion Ltd."></category><category term="Biogen Idec Inc."></category><category term="The Thomson Corporation"></category><category term="Semtech Corporation"></category><category term="New Jersey Supreme Court"></category><category term="A.G. Edwards Inc."></category><category term="Elan Corporation plc"></category><category term="Medarex Inc."></category><category term="Consumer Durables Manufacturing"></category><category term="Lexar Media Inc."></category><category term="Consumer Cyclicals"></category></entry></feed>
